Antisense Therapeutics Investor Briefing – 18 November
Antisense Therapeutics (ASX: ANP) Webcast Replay
Antisense Therapeutics (ASX: ANP) is an Australian biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
As a part of our ‘The Insiders’ series, CEO Mark Diamond provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 18 November 2020 at 12pm (AEDT).